McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

Article  CAS  PubMed  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089–1098

Article  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117–128

Article  PubMed  Google Scholar 

Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A et al (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22(4):713–722

Article  CAS  PubMed  Google Scholar 

Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN et al (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 23(7):1217–1225

Article  CAS  PubMed  Google Scholar 

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954–1960

Article  PubMed  PubMed Central  Google Scholar 

Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE et al (2020) Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med 173(6):417–425

Article  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

Article  CAS  PubMed  Google Scholar 

Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516–525

Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140(18):1463–1476

Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L et al (2021) Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol 6(7):836–840

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28(3):568–574

Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS et al (2022) Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 80(14):1302–1310

Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54(12):3427–3434

Article  CAS  PubMed  Google Scholar 

Chao EC, Henry RR (2010) SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov 9(7):551–559

Article  CAS  PubMed  Google Scholar 

Farber SJ, Berger EY, Earle DP (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30(2):125–129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N et al (2013) Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15(5):432–440

Article  CAS  PubMed  Google Scholar 

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27(5):479–484

Article  PubMed  Google Scholar 

Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K et al (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30(6):1109–1119

Article  CAS  PubMed  Google Scholar 

Bhatia J, Gamad N, Bharti S, Arya DS (2014) Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J Diabetes 5(3):399–406

Article  PubMed  PubMed Central  Google Scholar 

Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941–950

Article  CAS  PubMed  Google Scholar 

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF (2013) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27(5):473–478

Article  PubMed  Google Scholar 

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15(12):1154–1160

Article  CAS  PubMed  Google Scholar 

FDA (2013) Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf

Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Köves B, Schubert S, Pilatz A, Veeratterapillay R, Wagenlehner F, Guidelines Associates; Devlies W, Horváth J, Mantica G, Mezei T, Pradere B (2022) EAU guidelines on urological infections. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2022.pdf

Joshi N, Caputo GM, Weitekamp MR, Karchmer AW (1999) Infections in patients with diabetes mellitus. N Engl J Med 341(25):1906–1912

Article  CAS  PubMed  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

Article  CAS  PubMed  Google Scholar 

Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682

Article  PubMed  Google Scholar 

Cosentino CB, Mitchell BG, Brewster DJ, Russo PL (2021) The utility of frailty indices in predicting the risk of health care associated infections: a systematic review. Am J Infect Control 49(8):1078–1084

Article  PubMed  Google Scholar 

Chao CT, Lee SY, Wang J, Chien KL, Huang JW (2021) Frailty increases the risk for developing urinary tract infection among 79,887 patients with diabetic mellitus and chronic kidney disease. BMC Geriatr 21(1):349

Article  PubMed  PubMed Central  Google Scholar 

Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol 78(13):1337–1348

Article  PubMed  Google Scholar 

FDA (2015) Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm

Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC et al (2016) SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 38(12):2654–64.e1

Article  CAS  PubMed  Google Scholar 

Musso G, Saba F, Cassader M, Gambino R (2020) Diabetic ketoacidosis with SGLT2 inhibitors. BMJ 371:m4147

Article  PubMed  Google Scholar 

Mannucci E, Monami M (2017) Bone fractures with sodium-glucose co-transporter-2 inhibitors: how real is the risk? Drug Saf 40(2):115–119

Article  CAS  PubMed  Google Scholar 

Schmedt N, Andersohn F, Walker J, Garbe E (2019) Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case–control study. Diabetes Obes Metab 21(1):52–60

Article  CAS  PubMed  Google Scholar 

Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3(1):8–10

Article